Assay for isolation of inhibitors of her2-kinase expression

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Human Epidermal growth factor Receptor 2 (Her2/ErbB2) protein overexpression is common in breast and other solid tumors, correlating with disease progression.
• Existing Her2-targeted therapies focus on receptor dimerization blockade or tyrosine kinase inhibition to disrupt signaling pathways.
• Alternative strategies, such as inducing protein degradation or inhibiting synthesis, for suppressing Her2 expression remain underexplored.

Purpose of the Study:

• To develop and describe a novel hybrid western-blotting and enzyme-linked immunosorbent assay (ELISA).
• To establish a low- to medium-throughput method for identifying noncytotoxic compounds that reduce Her2 protein levels.

Main Methods:

• Utilized a combination of western-blotting and ELISA techniques.
• Screened compounds for their ability to decrease Her2 protein expression without inducing cytotoxicity.
• Implemented a low- to medium-throughput screening format.

Main Results:

• Successfully developed a hybrid assay for Her2 expression analysis.
• Identified noncytotoxic compounds capable of reducing Her2 protein levels.
• Established a feasible method for screening potential Her2-lowering agents.

Conclusions:

• The developed hybrid assay provides a valuable tool for discovering novel therapeutic strategies targeting Her2.
• This approach offers an alternative to current therapies by focusing on reducing Her2 protein expression.
• The method facilitates the identification of compounds that may suppress Her2 through degradation or synthesis inhibition.